Loading...

          

51 American Society of Hematology - New Orleans, December 5-8, 2009
Loading...
How to treat elderly patients: combination therapy or sequencing  »    PDF - 390 KB

Antonio Palumbo, MD
University of Torino, Torino, Italy, EU
A prospective, randomized study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan 200 mg/m2 (MEL200) in newly diagnosed myeloma patients: an interim analysis  »    PDF - 355 KB

Antonio Palumbo1, Federica Cavallo2, Dina Ben Yehuda2, Paola Omede2, Agostina Siniscalchi2, Maide Cavalli2, Barbara Lupo2, Aaron Polliack2, Izhar Hardan2, Fabiana Gentilini2, Paolo Corradini2, Claudia Crippa2, Fausto Rossini2, Francesca Patriarca2, Annalisa Citro2, Alessandro Petrucci2, Angelo Michele Carella2, Giulia Benevolo2, Tommaso Caravita2, Francesco Di Raimondo2, Mario Boccadoro2
1. Division of Hematology, University of Torino, Torino, Italy, EU
2. European Myeloma Network, EU
Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) followed by maintenance with Bortezomib and Thalidomide (VT) for initial treatment of elderly multiple myeloma patients  »    PDF - 402 KB

A. Palumbo1, S. Bringhen1, D. Rossi2, R. Ria2, M. Offidani2, F. Patriarca2, C. Nozzoli2, A. Levi2, T. Guglielmelli2, G. Benevolo2, V. Callea2, B. Olivero2, F. Morabito2, M. Grasso2, R. Marasca2, M. Rizzo2, A. Falcone2, D. Gottardi2, V. Montefusco2, C. Musolino2, R. Zambello2, C. Cangialosi2, G. Pietrantuono2, V. Magarotto1, M.T. Petrucci2, P. Musto2, G. Ciccone2, F. Di Raimondo2, G. Gaidano2, M. Boccadoro1
1. Division of Hematology, University of Torino, Torino, Italy, EU
2. Italian Multiple Myeloma Network, GIMEMA, Italy
Phase 3b UPFRONT Study: Interim Results from a Community Practice-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients  »    PDF - 92 KB

Ruben Niesvizky1, James Reeves2, Ian Flinn3, Robert Rifkin4, Billy Clowney5, Nashat Gabrail6, Vijay Phooshkooru7, Veena Charu8, Christopher Chay9, Deyanira Corzo10, Rachel Neuwirth10, Robert Manges11, Thomas Warr12, on behalf of the UPFRONT Study Group
1. Center of Excellence for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital, NY
2. Florida Cancer Specialists, Bonita Springs, FL
3. Sarah Cannon Research Institute, Nashville, TN
4. Rocky Mountain Cancer Centers, US Oncology, Denver, CO
5. Santee Hematology/Oncology, Sumter, SC
6. Gabrail Cancer Center, Canton, OH
7. Mid Dakota Clinic, Bismarck, ND
8. Pacific Cancer Medical Center, Anaheim, CA
9. Cancer Care of WNC, Asheville, NC
10. Millennium Pharmaceuticals, Inc., Cambridge, MA
11. Investigative Clinical Research of Indiana, Indianapolis, IN
12. Clinic Cancer Care, Great Falls, MT
A Phase 1b Multicenter Dose Escalation Study of Carfilzomib plus Lenalidomide and Low-dose Dexamethasone in Relapsed Multiple Myeloma  »    PDF - 409 KB

R. Niesvizky1, M. Wang2, W. Bensinger3, M. Alsina4, N Gabrail5, M. Vallone6, A.A. Gutierrez6, M. Kauffman6
1. Weill Cornell Medical College, New York, NY
2. MD Anderson Cancer Center, Houston, TX
3. Fred Hutchinson Cancer Research Center, Seattle, WA
4. H. Lee Moffitt Cancer Center & Research Center, Tampa, FL
5. Gabrail Cancer Center, Canton, OH
6. Onyx Pharmaceuticals, Inc., Emeryville, CA
A Phase 3 Historically-Controlled Clinical Trial Investigating the Use of Defibrotide (DF) in the Treatment of Severe Veno-Occlusive Disease Following SCT  »    PDF - 203 KB

P G Richardson, MD1, M Tomblyn, MD2, N Kernan, MD3, J Brochstein, MD4, S Mineishi, MD5, A Termuhlen, MD6, S Arai, MD7, S Grupp MD8, E Guinan, MD1, P Martin, MD9, S Corbacioglu MD10, E Holler MD11, R D'Agostino, PhD12, J Massaro PhD12, A Hannah, MD13, M Iacobelli, MD13, R Soiffer, MD1
1. Dana-Farber Cancer Ctr, Mass General, Children's Hosp, Boston, MA
2. Univ Minnesota Cancer Ctr, Minneapolis, MN
3. Memorial Sloan-Kettering Cancer Ctr, New York, NY
4. Hackensack Univ Med Ctr, Hackensack, NJ
5. Univ Michigan, Ann Arbor MI
6. Nationwide Children’s Hospital
7. Stanford Univ Med Ctr, Stanford, CA
8. Children’s Hosp of Philadelphia, Philadelphia PA
9. Duke Univ Med Ctr, Durham, NC
10. Univ Ulm, Ulm, Germany
11. Klinikum der Univ Regensburg, Regensburg, Germany
12. Boston Univ, Boston, MA
13. Gentium,SpA, Villa Guardia, Como, Italy
Changes in serum free light chain rather than intact monoclonal immunoglobulin levels predict outcome with therapy in patients with light chain amyloidosis  »    PDF - 792 KB

Shaji Kumar, Morie Gertz, Martha Lacy, Suzanne Hayman, Francis Buadi, Steven Zeldenrust, Marina Ramirez-Alvarado, Nelson Leung, Angela Dispenzieri
Mayo Clinic
Time Trends in Allogeneic Stem Cell Transplantation for Multiple Myeloma: A CIBMTR Analysis  »    PDF - 157 KB

Shaji Kumar, MD*
Mayo Clinic, Rochester, MN
*On behalf of the Plasma Cell Disorders Working Committee,
Center for International Blood and Marrow Transplant Research
Management of Myeloma at Relapse  »    PDF - 1,73 MB

A. Keith Stewart
Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse vs. Early Transplantation  »    PDF - 1,69 MB

Shaji Kumar, Martha Q. Lacy, Angela Dispenzieri, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Francesca Gay, William Hogan, S. Vincent Rajkumar, Morie A Gertz
Mayo Clinic
How to treat a newly diagnosed young patient with multiple myeloma  »    PDF - 474 KB

J.F. San Miguel
University of Salamanca, Spain
Novel Three- and Four-Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Results from the Multi-Center, Randomized, Phase 2 EVOLUTION Study  »    PDF - 141 KB

Shaji Kumar1, Ian Flinn2, Parameswaran Hari3, Natalie Callander4, Stephen J Noga5, A Keith Stewart6, Jonathan Glass7, Noopur Raje8, Robert Rifkin9, Hongliang Shi10, Iain J Webb10, Paul G Richardson11, S Vincent Rajkumar1
1. Division of Hematology, Mayo Clinic, Rochester, MN
2. Sarah Cannon Research Institute, Nashville, TN
3. Medical College of Wisconsin, Milwaukee, WI
4. University of Wisconsin Comprehensive Cancer Center, Madison, WI
5. Sinai Hospital of Baltimore, Baltimore, MD
6. Mayo Clinic Arizona, Scottsdale, AZ
7. Louisiana State University Health Sciences Center, Shreveport, LA
8. Massachusetts General Hospital, Boston, MA
9. Rocky Mountain Cancer Centers, Denver, CO
10. Millennium Pharmaceuticals, Inc., Cambridge, MA
11. Dana-Farber Cancer Institute, Boston, MA
A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Pts With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib; Preliminary Results  »    PDF - 139 KB

Paul Richardson1, David Siegel2, Rachid Baz3, Susan L Kelley4, Nikhil C Munshi1, Daniel Sullivan3, Laura McBride2, Deborah Doss1, Gail Larkins5, Christian Jacques5, Arlene Donaldson5, Kenneth C Anderson1
1. Dana-Farber Cancer Institute, Boston, MA
2. Hackensack University Medical Center, Hackensack, NJ
3. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
4. Multiple Myeloma Research Consortium, Norwalk, CT
5. Celgene Corporation, Summit, NJ
Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM)  »    PDF - 1,2 MB

Paul Richardson MD, Craig Hofmeister MD, Andrzej Jakubowiak MD PhD, Todd M. Zimmerman MD, Matthew A. Spear MD, Sagar Lonial MD, Jonathan Kaufman MD, Asher Chanan-Khan MD, Michael A. Palladino PhD, Angie M. Longenecker RN BSN, Susan L. Kelley MD, Saskia Neuteboom PhD, Gillian F Cropp MSc, G. Kenneth Lloyd PhD, Alison L. Hannah MD, Kenneth C. Anderson MD
Dana Farber Cancer Institute, Boston, MA
Ohio State University, Columbus, OH
University of Michigan, Ann Arbor, MI
University of Chicago, Chicago, IL
Winship Cancer Center, Atlanta, GA
Roswell Park Cancer Institute, Buffalo, NY
Multiple Myeloma Research Consortium, Norwalk, CT
Nereus Pharmaceuticals, Inc., San Diego, CA




Prepared: Artur Jurczyszyn MD PhD

Cracow, ‏17 December 2009



حساب جاری زلات لهستان  :  06 1440 1127 0000 0000 0835 9709